Recent

% | $
Quotes you view appear here for quick access.

Santarus, AŞ Message Board

  • nasdtechanalyst nasdtechanalyst Sep 13, 2013 12:21 PM Flag

    Speculative biotechs doing much better than FDA approved pills

    speculative plays
    CLDX
    PRAN
    RMTI
    ACAD
    INCY

    FDA Approved ones
    ISRG
    SNTS
    DEAD MONEY

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • PRAN today?, you are a fool. SNTS is better, we will see in time.

    • We never know which way you are playing this. Long? Short?

      You are comparing apples to oranges amigo.

      The intrinsic value of SNTS IS 2 Billion in market cap. This is a gift.
      The speculative bios always trade differently.

      But let me ask you this. When the tide goes out, who is left with their pants down? The spec bios crash and burn and the companies with proven earnings hold their value.

      Sentiment: Strong Buy

      • 1 Reply to rick449
      • you are right about this, I agree with you.
        Final thoughts
        If three times peak sales is the standard for biotechnology companies -- based on Pharmacyclics and Ariad -- then Santarus should trend higher until reaching a market capitalization of $2.7 billion. This would be a gain of almost 100% from this point forward. Therefore, I say that Santarus' recent pullback is just a bump in the road and not a serious threat of long-term loss. With that said, investors should keep this company on their radar. With Uceris' marketing success and Santarus' five clinical programs in development, this is a company with a lot of promise regardless of its short-term trend.